Baricitinib treatment induces significant, dose-dependent pharmacodynamic changes in macrophage-related and matrix-regulating serum proteins in patients with JIA.
Reductions in CCL7, CCL18, IL-6, and Matrix Metalloproteinase-3 (MMP-3) levels correlate strongly with clinical improvement as measured by JADAS-27 scores.
The magnitude of biomarker change distinguishes clinical ‘super-responders’ from non-responders, providing a potential framework for monitoring therapeutic efficacy.
This study represents the first large-scale proteomic analysis of baricitinib response in a pediatric rheumatology clinical trial setting.
Background: The Challenge of Heterogeneity in JIA
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.